Neurotech International (ASX:NTI) - Hisse Senedi Fiyatı, Haberler ve Analizler

NTI Stoklara Genel Bakış

NTI temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 44.67% oranında artması öngörülüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir geliri yok ( A$3M )

Anlamlı bir piyasa değeri yok ( A$72M )

Neurotech International Limited Rakipler

CurveBeam AI

ASX:CVB

AU$45.2m

Micro-X

ASX:MX1

AU$33.2m

EMVision Medical Devices

ASX:EMV

AU$167.6m

Austco Healthcare

ASX:AHC

AU$91.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Neurotech International
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.07
52 Haftanın En Yüksek Seviyesi	AU$0.13
52 Haftanın En Düşük Seviyesi	AU$0.048
Beta	1.48
11 Aylık Değişim	34.62%
3 Aylık Değişim	1.45%
1 Yıllık Değişim	22.81%
33 Yıllık Değişim	22.81%
5 Yıllık Değişim	337.50%
Halka arzdan bu yana değişim	-75.44%

Son Haberler & Güncellemeler

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

Hissedar Getirileri

	NTI	AU Medical Equipment	AU Pazar
7D	1.4%	4.1%	1.5%
1Y	22.8%	13.4%	17.9%

Getiri vs. Endüstri: NTI geçen yıl % 13.4 oranında getiri sağlayan Australian Medical Equipment sektörünü aştı.

Getiri vs Piyasa: NTI geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	8.8%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: NTI son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: NTI 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Klinik aşamada bir biyofarmasötik geliştirme şirketi olan Neurotech International Limited, Avustralya'da tıbbi cihaz ve çözümlerin araştırılması, tasarlanması, geliştirilmesi ve üretilmesi faaliyetlerini yürütmektedir. Şirket, çoklu pediatrik nörolojik bozukluklar için NTI164'ün ve yüksek delta bandı beyin aktivitesi sergileyen otistik çocuklarda katılımı ve rahatlamayı artırmayı amaçlayan klinik olarak kanıtlanmış bir ev terapisi olan Mente'nin geliştirilmesine ve ticarileştirilmesine odaklanmıştır. Şirket ayrıca tıbbi araştırma projeleri yürütmekte ve teknolojik cihazlar geliştirmektedir.

Neurotech International Limited Temel Bilgiler Özeti

Neurotech International'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NTI temel i̇stati̇sti̇kler
Piyasa değeri	AU$72.42m
Kazançlar(TTM)	-AU$5.07m
Gelir(TTM)	AU$3.18m

22.8x

P/S Oranı

-14.3x

F/K Oranı

NTI aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NTI gelir tablosu (TTM)
Gelir	AU$3.18m
Gelir Maliyeti	AU$7.83k
Brüt Kâr	AU$3.17m
Diğer Giderler	AU$8.24m
Kazançlar	-AU$5.07m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.0049
Brüt Marj	99.75%
Net Kâr Marjı	-159.54%
Borç/Özkaynak Oranı	0%

NTI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NTI Stoklara Genel Bakış

Ödüller

Risk Analizi

Neurotech International Limited Rakipler

ASX:CVB

AU$45.2m

ASX:MX1

AU$33.2m

ASX:EMV

AU$167.6m

ASX:AHC

AU$91.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.